Anti-TRP1 Mouse Monoclonal Antibody (Clone TA99)

SK 413

Anti-TRP1 Mouse Monoclonal Antibody (Clone TA99)

SK 413
Antigen:                                Human TRP1 (TYRP1, PAA, gp75)
Clone Name:                        TA99
Isotype:                                  Mouse IgG2a
Application(s):                   Immunocytochemistry, Immunohistochemistry, Immunoprecipitation, Western Blot
Reactivity*:                          Mouse, Human
* As reported in the literature and other commercial supplier websites


Clone TA99 is a mouse monoclonal antibody that reacts with tyrosinase-related protein 1 (TRP1), a 75kDa differentiation-related human glycoprotein (gp75), formerly referred to as pigmentation-associated antigen (PAA).  It is expressed by pigmented melanoma cells and cultured melanocytes. TRP1 is involved in the pigmentation machinery of melanocytes and can be used as a differentiation marker.


This antibody was derived in 1985 by injection of whole human melanoma cells (SK-MEL-23) into mice. Splenocytes from these immunized mice were fused with NS-1 cells to generate hybridomas producing anti-TRP1 antibodies.


  • Francisco X. Real, MD, PhD, formerly at Memorial Sloan Kettering
  • Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Timothy M. Thomson, MD, PhD

Key References

  • Thomson TM et al. (1985) Pigmentation-Associated Glycoprotein of Human Melanomas and Melanocytes: Definition with a Mouse Monoclonal Antibody. Journal of Investigative Dermatology 85: 169-174 (PubMed ID: 3926906)
  • Bevaart L et al. (2006) The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Research 66: 1261-1264 (Pubmed ID: 16452176)

Licensing Information

This hybridoma may be licensed nonexclusively for commercial purposes. For more information, please contact [email protected].

Additional Information

Purified antibody may be available for sale through the Memorial Sloan Kettering Antibody & Bioresource Core Facility.  Please email [email protected] for further information.

Stage of Development

Ready to use